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disruption, irrespective of the genetic
predisposition of the keratinocytes
(normal, psoriasis, or AD background).
This phenomenon may possibly depend
on the massive damage-induced release
of preformed cytosolic stimuli, such as
IL-1a. Modifying factors such as genetic
programming (for example, filaggrin or
LCE3B/C deficiency, differential sensi-
tivity to cytokines) and cytokine envir-
onment could have a role in the repair
process, which may be qualitatively
different in psoriasis and AD. Contin-
ued barrier deficiency will stimulate the
production of factors that induce in-
flammation and recruitment of immune
cells, eventually including Th1/Th17
cells in psoriasis and mainly Th2 cells
in AD. This process will also determine
epidermal host defense gene expres-
sion levels: a full-blown antimicrobial
defense in psoriasis or a dampened
antimicrobial response that promotes
skin colonization and superinfection as
observed in AD.
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TO THE EDITOR
Sphingosine-1-phosphate (S1P) is a
unique lipid in that on the one hand it
is part of the lipid fraction securing the
epidermal permeability barrier and on
the other hand, it has been shown to act
as a critical signaling molecule and to
elicit a variety of partially contrasting
cellular effects. The significance of S1P
in immune cell regulation became
obvious when it was discovered that
the novel immunosuppressive drug
FTY720 (fingolimod) causes lymphope-
nia via S1P signaling (Mandala et al.,
2002). In skin, sphingosine can be
cleaved from ceramides, which account
for 30–40% of stratum corneum lipids
(Herzinger et al., 2007). Sphingosine
can then be phosphorylated by sphingo-
sine kinases to S1P, which binds to a
family of G-protein-coupled receptors,
termed S1P1–S1P5. S1P signaling is
irreversibly inactivated by an S1P lyase.Abbreviation: S1P, sphingosine-1-phosphate
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In a recent study, we demonstrated
the action of topically administered S1P
in a murine model of allergic contact
dermatitis. Interestingly, S1P inhibited
the inflammatory reaction in the elicita-
tion phase of allergic contact dermati-
tis. In the sensitization phase, S1P
reduced the weight and cell count of
the draining auricular lymph node, as
well as of immigrated dendritic cells
provoked by repetitive topical adminis-
tration of the hapten. Correspondingly,
the density of Langerhans cells in the
epidermis was higher in S1P-treated
mice than in mice treated with vehicle
(Reines et al., 2009).
In the light of previous reports
suggesting that S1P-lyase activity is
altered in atopic lesions in humans
(Seo et al., 2006) and dogs (Wood
et al., 2009), the present study was
performed to determine the concentration
of S1P in plasma and healthy skin
compared with plasma and lesional skin
of dogs with atopic dermatitis in order to
evaluate a possible imbalance in the
S1P–S1P–lyase axis in atopic dermatitis.
With the consent of the owners, eight-
millimeter biopsy punches were taken
from the inguinal region of five atopic
dogs. (Supplementary Table S1 online
lists the sex, breed, and age of each
dog.) Atopic dermatitis was diagnosed
by excluding flea allergy and adverse
food reactions as well as by skin biopsy
and blood testing. Immediately after
euthanasia, healthy skin was taken from
the inguinal area of dogs, which had to
be killed for reasons not related to this
study. Alternatively, skin was taken,
which had to be removed within a
surgery procedure. Epidermal pieces
taken from the biopsied samples
were homogenized in culture medium.
A portion of the homogenate was spiked
with S1P. One nonspiked sample and
one S1P-spiked sample were taken after
thorough mixing and frozen at 201C
until measurement of S1P. The remain-
ing two samples were cultivated at
371C, in 5% CO2 for 24 hours, and then
frozen at 201C. S1P was measured as
previously described (Ruwisch et al.,
2001; Reines et al., 2009).
The mean concentration of S1P in
homogenized epidermis from healthy
skin was 0.63 nmol per mg protein. The
mean concentration of S1P in lesional
skin was significantly lower, 0.18 nmol
per mg protein (Figure 1a), whereas the
concentration of sphingosine is com-
parable in the two groups (1.49±0.92
nmol mg1 in healthy skin vs. 1.48±
0.99 nmol mg1 in atopic skin). Directly
after spiking with S1P, there was a
comparable concentration of S1P in
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Figure 1. Concentration of sphingosin-1-phosphate (nmol of S1P per mg protein) in the epidermis of healthy skin and lesional skin of dogs suffering
from atopic dermatitis. (a) When epidermal skin homogenate was spiked with S1P, there was a significantly higher degradation of S1P in the lesional epidermis of atopic
dogs (b). There was also a significantly lower concentration of S1P in the plasma of dogs with atopic dermatitis (c). n¼ 5 (4 for plasma values) in
each group. *Po0.05, ***Po0.001.
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samples of healthy and lesional
skin (2.95±0.40 nmol mg1 and 2.45±
0.21 nmol mg1, respectively). How-
ever, 24 hours after incubation at 371C
there was a nonsignificant decrease
in samples of nonlesional skin (2.07±
0.19 nmol mg1), whereas S1P dec-
reased significantly in lesional skin
(1.16±0.22 nmol mg1). The percen-
tage of decrease was significantly high-
er in atopic lesions (28% decrease of
S1P in healthy skin vs. 53% decrease in
lesional skin (Figure 1b)).
In the plasma of dogs with healthy
skin, the mean concentration of S1P
was 72.9 pmol 100 ml1. The concen-
tration was significantly lower—53.4
pmol 100ml1—in dogs suffering from
atopic dermatitis (Figure 1c). This
was confirmed in a separate experi-
ment using the serum of nine other
dogs (21.5 pmol 100ml1 in dogs with
healthy skin vs. 14.5 pmol 100 ml1 in
dogs with atopic dermatitis; Po0.05).
The results of this study suggest an
imbalance in the S1P–S1P–lyase axis in
atopic dermatitis. In a recent review
(Kumar and Saba, 2009), S1P lyase
was also characterized as a potential
therapeutic target for immunological
disorders, which is in accordance with
the imbalance that we observed. It is
noteworthy that the variation in S1P
concentration in the skin of healthy
dogs was so small given the wide
variation in breeds and age (1.8–12
years) of the dogs studied. Similarly, the
concentration range of S1P in lesional
skin was very narrow in spite of the
variety of breeds and ages (1–5 years).
This is indicative of a very robust and
significant alteration in atopic dogs,
which is reflected in the altered plasma
concentration.
The findings are consistent with the
enhanced S1P-lyase activity found in
mRNA of lesional skin from human
atopic dermatitis patients (Seo et al.,
2006). In a gene expression study in
dogs with atopic dermatitis, a signifi-
cant difference in mRNA expression
between atopic and healthy skin was
found for S1P lyase (Wood et al., 2009).
However, unlike in human skin, the
mRNA expression was downregulated
rather than upregulated.
To rule out the possibility that S1P was
dephosphorylated by the S1P phosphatase,
sphingosine was measured in the homo-
genate of spiked samples. There was
only a marginal increase of sphingosine
within 24 hours of incubation (11.2±
1.6 nmol mg1 to 13.5±1.3 nmol mg1
in healthy skin vs. 12.1±1.4 nmol mg1
to 13.3±1.5 nmol mg1 in atopic der-
matitis), which indicates that S1P was
not extensively dephosphorylated but,
instead, metabolized by S1P lyase,
resulting in a vastly reduced S1P con-
centration in dog skin with acutely
affected atopic lesions (Figure 1a). Thus,
it can be speculated that topical S1P has
local immunosuppressive activity in the
epidermis and that reduced S1P levels
by enhanced S1P-lyase activity in skin
might be involved in activation of
Langerhans cells.
With regard to allergic diseases such
as atopic dermatitis, it can be postulated
that topical administration of S1P may
be beneficial. Another promising aspect
of topical administration is the effect of
S1P on keratinocytes. S1P reduces pro-
liferation and induces differentiation of
keratinocytes. The hyperproliferative
epidermis in chronic skin lesions resem-
bling lichenification (Olivry and Hill,
2001) might be another therapeutic
target, given S1P’s potential to restore
keratinocyte homeostasis (Herzinger
et al., 2007; Schuppel et al., 2008).
It is interesting that the plasma
concentration of S1P is also reduced;
this indicates a systemic dysregulation
of the S1P pathway, possibly stemming
from genetic predisposition.
With regard to atopic dermatitis, it is
noteworthy that there exist several
similarities (as well as some differences)
between the canine and human forms
of the condition, as described in detail
in a recently published review (Marsella
and Girolomoni, 2009). Considering the
enhanced S1P-lyase mRNA in atopic skin
lesions in humans (Seo et al., 2006),
it would be worthwhile to determine
the exact concentrations of S1P and
lyase products in the skin and plasma of
humans with atopic dermatitis.
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